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Purpose: To identify the characteristic quadriphasic (unenhanced, corticomedullary, 
nephrographic, and excretory phase) helical multidetector computed tomography 
(MDCT) features of renal masses less than 4 cm to distinguish benign from malignant 
renal masses.
Materials and Methods: In total, 84 patients were retrospectively analyzed to de-
termine the characteristic features for the prediction of subtypes of small renal masses. 
The patients’ age, gender, and tumor size and CT features, including the presence of 
intra-tumor degenerative changes, septation, calcification, and wall irregularity, were 
evaluated. In addition, the degree and pattern of enhancement obtained during four 
phases were analyzed. The relationship between the subtype of the small renal masses 
and the gender, morphological features, and pattern of contrast enhancement on the 
CT was analyzed by using the chi-square test. Tumor size and degree of contrast en-
hancement were compared by the Mann-Whitney U test. The predictive value of each 
of the CT features was determined by multivariate logistic regression analysis.
Results: Of the 84 small renal masses, 17 (20%) were benign and 67 (80%) were 
malignant. Univariate analysis revealed that renal cell carcinoma lesions showed het-
erogeneous enhancement (p=0.002) and higher mean attenuation value on the cortico-
medullary and nephrographic phases (135.1±53.9, p=0.000, and 132.4±43.6, p=0.006). 
The multivariate analysis with logistic regression model showed that only the mean 
attenuation value on the corticomedullary phase had a statistically significant correla-
tion (p=0.021).
Conclusions: For the characterization of small renal masses, the degree of enhancement 
on the corticomedullary phase is a valuable parameter. Furthermore, the heteroge-
neous enhancement pattern and degree of enhancement on the nephrographic phase 
can provide information for differentiating small renal masses.
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INTRODUCTION
With the widespread use of cross-sectional imaging modal-
ities, an unprecedented number of incidental small renal 
masses have been identified. Although simple cysts ac-
count for the majority of these lesions, there are also a large 
number of malignancies. Therefore, differentiation of be-
nign from malignant lesions has become an important 
issue.
Computed tomography (CT) remains the most useful 
imaging modality for the assessment of renal masses; CT 
provides an accurate evaluation of tumor size, location, or-
gan confinement, status of the tumor wall, and margin 
irregularity. Helical multidetector CT (MDCT) has sig-Korean J Urol 2012;53:159-164
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nificantly improved the imaging of renal masses by de-
creasing respiratory misregistration and allowing rapid 
volumetric data acquisition free of skip areas. Further-
more, MDCT has expanded multiphasic scanning capa-
bilities while at the same time providing superior axial res-
olution and multiplanar reformation options with very 
thin collimation. This technology might allow for the analy-
sis of the degree and pattern of dynamic contrast enhance-
ment from identical levels in the kidney at each phase [1]. 
Therefore, previously undetectable or indeterminate find-
ings with conventional CT are better characterized by 
MDCT.
Some studies have been carried out to differentiate be-
tween small benign renal masses and malignancies less 
than 4 cm in diameter by use of MDCT. For instance, renal 
oncocytomas, which are benign tumors, might be treated 
conservatively if a definitive noninvasive diagnosis can be 
made. Some literature has reported features of MDCT that 
can differentiate oncocytomas from renal cell carcinomas 
(RCCs) [2,3]. However, no definite criteria have been esta-
blished.
Our aim was to identify the characteristic quadriphasic 
[unenhanced, corticomedullary (CMP), nephrographic (NP), 
and excretory phase (EP)] helical MDCT features of small 
renal masses less than 4 cm to distinguish benign from ma-
lignant renal masses.
MATERIALS AND METHODS
1. Patient selection
We performed a retrospective review of the medical records 
and diagnostic imaging studies of 84 patients with patho-
logically confirmed solitary renal masses 4 cm or less in 
diameter. All patients had either open or laparoscopic re-
moval of a presumed unilateral, unifocal RCC at our in-
stitution between 2000 and 2009. All lesions were thought 
to be RCC on preoperative imaging as evaluated by an expe-
rienced genitourinary radiologist who was unaware of the 
surgical and histological findings. All patients had 
four-phase scans that were consecutively acquired by heli-
cal MDCT. The patients known preoperatively to have 
non-RCC lesions on CT, such as angiomyolipoma (AML), 
transitional cell carcinoma, or a benign nonfunctioning 
kidney, were excluded. No patient had a known history of 
von Hippel-Lindau disease, contralateral nephrectomy for 
RCC, or synchronous bilateral RCC.
2. MDCT scanning
All CT examinations were performed by using a helical CT 
scanner (GE Medical Systems LLC, Milwaukee, WI, USA). 
All patients had four-phase CT imaging that included an 
unenhanced scan before administration of intravenous 
contrast material injection and the evaluation of the CMP, 
NP, and EP after contrast material injection, which is the 
standard spiral CT protocol at our medical center. The CT 
protocol remained constant and consisted of volumetric da-
ta acquisition of the kidney using 5-mm thin collimation, 
a 0.5-s gantry rotation speed, a tube voltage of 120 kV, and 
a tube current of 200 to 240 mAs; table feed, 7 mm/s; and 
reconstruction interval, 3 mm.
All patients received 150 ml of intravenous contrast ma-
terial (iopromide, Ultravist 300, Bayer Schering Pharma, 
Berlin, Germany) by use of a dynamic bolus technique 
(injection into an antecubital vein by use of a power injector 
at a rate of 3.0 ml/s). The delay was 30 seconds for the CMP, 
70 seconds for the NP, and 180 seconds for the EP.
3. Image analysis
Axial and reformatted images were evaluated for the pres-
ence or absence of calcification within the lesion, attenu-
ation on the unenhanced scans, degenerative changes, sep-
tation, and margin irregularity. For evaluation of the de-
gree of enhancement, strict measurement of the attenu-
ation value was performed by use of a standard elliptic cur-
sor for the region of interest, placed in the center of the most 
enhanced solid portion, which was consistent in location 
during all phases of the MDCT and compared with that of 
the unenhanced scan. Precontrast attenuation was de-
termined by visual inspection and was classified as hy-
po-attenuation, iso-attenuation, and hyper-attenuation 
by comparison with the attenuation of the surrounding re-
nal parenchyma. We considered the tumor to be hyper-
attenuating when the difference in density was positive 
and greater than 10 HU, hypoattenuating when the differ-
ence was negative but still greater than 10 HU, and iso-
attenuating when the difference was less than 10 HU.
The degree of enhancement of each phase was measured 
by calculating the difference in the mean attenuation value 
between the CMP and the unenhanced scan, the NP and 
the unenhanced scan, and the EP and the unenhanced 
scan, respectively. 
The enhancement pattern was classified as homoge-
neous when most of the tumor areas showed a uniform de-
gree of enhancement on both the CMP and the NP. The en-
hancement pattern was classified as heterogeneous in the 
remaining cases.
4. Pathology examination and analysis
Histological sections were reviewed by consensus of two ex-
perienced pathologists using a double-headed light micro-
scope simultaneously. The histopathologic findings were 
reviewed for the subtype of neoplasm, the presence of in-
tra-tumor necrosis or hemorrhage, and the existence of 
septation.
5. Statistical methods
Statistical analysis was performed with SPSS ver. 12.0 
(SPSS, Chicago, IL, USA). The relationship between the 
subtype of the small renal masses and the gender, morpho-
logical features, and pattern of contrast enhancement on 
the CT was analyzed by using the chi-square test. Tumor 
size and degree of contrast enhancement were compared 
by the Mann-Whitney U test. To assess the predictive value 
of various characteristics observed on the MDCT that sig-Korean J Urol 2012;53:159-164
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TABLE 1. Patient demographic and clinical data 
　 Benign Malignant  p-value 
No. of patients  (%)  
Age  (yr) 
Male/Female, no. (%)
Renal mass 
    Pathology, no. (%) 
　
　
　
    Size (cm) 
    Laterality (right/left), no. (%) 
    Contour, no. (%) 
        Exophytic  
        Endophytic  
    Location, no. (%) 
        Upper pole  
        Mid pole  
        Lower pole  
17 (20) 
61.3±13.9 
  7/10 (41/59)
AML 6 (35) 
Oncocytoma 8 (47) 
Cortical adenoma 2 (12) 
Infected cyst 1 (6) 
2.41±0.73 
  7/10 (41/59) 
  9 (53) 
  8 (47) 
  6 (35) 
  4 (24) 
  7 (41) 
67 (80) 
63.2±11.5 
50/17 (75/25)
Clear cell RCC 57 (85)   
Papillary RCC 4 (6) 
Chromophobe RCC 5 (7) 
Collecting duct RCC 1 (2) 
2.74±0.65 
33/34 (49/51) 
44 (66) 
23 (34) 
22 (33) 
24 (36) 
21 (31) 
0.680
0.002
0.072
0.551
0.331
0.741
Values are presented as number (%) or mean±SD.
AML, angiomyolipoma; RCC, renal cell carcinoma.
TABLE 2. MDCT features of small renal masses
　
Benign
(n=17)
Malignant
(n=67)
p-value
Calcification, no. (%) 
Cystic degeneration, 
no. (%)
Septation, no. (%) 
Wall irregularity, no. 
(%)
Attenuation in NEC, 
no. (%)
    Hypoattenuation  
    Isoattenuation  
    Hyperattenuation 
Enhancement 
pattern, no. (%)
    Homogeneous  
    Heterogeneous  
Hounsfield unit
    HU at NEC
    HU at CMP
    HU at NP
    HU at EP
0
0
0
0
1 (6) 
15 (88) 
1 (6)
14 (82) 
  3 (18) 
32.58±7.82
  92.88±41.18
  89.47±42.40
  90.17±33.52
6 (9)
17 (25)
  7 (10)
5 (8)
  8 (12) 
51 (76) 
  8 (12) 
25 (37) 
42 (63) 
  29.58±10.59
135.16±53.90
132.49±43.64
102.29±31.44
　
1.000
0.002
0.122
0.000
0.006
0.071
Values are presented as number (%) or mean±SD.
MDCT, multidetector computed tomography; HU, Hounsfield 
unit; NEC, nonenhanced CT; CMP, corticomedullary phase; NP, 
nephrographic phase; EP, excretory phase.
nificantly differentiated RCC from benign renal masses, 
multivariate logistic regression analysis was performed. 
To evaluate the diagnostic efficacy of the degree of enhance-
ment during the various phases of enhancement, receiver 
operating characteristic (ROC) curves were generated. 
The curves were analyzed to determine the cutoff value 
during four phases for differentiating malignancies from 
small benign renal masses with the highest accuracy. 
p-values of less than 0.05 were regarded as statistically 
significant. 
RESULTS
1. Descriptive analysis
The mean patient age was 63.2±11.5 years (range, 32 to 83 
years) in the patients with RCC and 61.3±13.9 years 
(range, 31 to 75 years) in those with benign lesions (p＞
0.05). The male-to-female ratio was 2.9:1 for the patients 
with RCC and 0.7:1 for the patients with benign lesions 
(p=0.002). The mean diameter of the renal masses, ob-
tained from the preoperative MDCT, was 2.74±0.68 cm 
(range, 1 to 4 cm) for RCC and 2.41±0.73 cm (range, 1.5 to 
3.8 cm) for benign lesions (p＞0.05). On the basis of the 
pathology reports, of the 84 small renal masses, 17 (20%) 
were benign and 67 (80%) were malignant. The benign le-
sions consisted of eight oncocytomas, six AML, two cortical 
adenomas, and one infected mass. The 67 RCCs were of the 
following subtypes: 57 (85%) clear cell, 4 (6%) papillary, 5 
(8%) chromophobe, and 1 (1%) collecting duct. A histo-
pathology examination of the small RCCs revealed that 44 
tumors were mostly grade 1 and grade 2 (66%); 22 (33%) 
tumors were grade 3, and 1 was grade 4. The demographic 
information was not significantly different between the be-
nign and malignant small renal masses, except for gender 
(Table 1).
2. Morphologic features on the MDCT
Cystic degeneration, calcification, septation, and wall ir-
regularity showed only in cases with RCC. Table 2 summa-Korean J Urol 2012;53:159-164
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TABLE 3. Multivariate analysis with logistic regression model
p-value Exp (B)
95% CI for EXP (B)
Lower Upper
Sex
Enhancement pattern
HU CMP
HU NP
0.017
0.055
0.021
0.519
5.156
0.265
0.975
1.009
1.347
0.068
0.954
0.982
19.737
  1.027
  0.996
  1.037
CI, confidence interval; HU, Hounsfield unit; CMP, cortico-
medullary phase; NP, nephrographic phase.
FIG. 1. Receiver operating characteristic (ROC) curves for the 
degree of contrast enhancement as a distinguishing factor 
between small malignant masses and small benign masses. The 
area under the curve for the corticomedullary phase (CMP) was 
0.785 (95% confidence interval [CI], 0.667 to 0.902), which was 
statistically significant, and that for the nephrographic phase 
(NP) was 0.717 (95% CI, 0.579 to 0.854). CMP, corticomedullary 
phase; NP, nephrographic phase.
rizes a comparison between the features of benign and ma-
lignant lesions.
3. Pattern and degree of contrast enhancement
The 67 RCCs had a mean attenuation value of 29.5±10.5 
HU on the unenhanced scan (range, 5 to 50 HU). All carcino-
mas showed significant contrast enhancement (more than 
20 HU) after intravenous injection of contrast [mean en-
hancement during CMP: 135.1±53.9 HU [range, 47 to 288 
HU]; mean enhancement during NP, 132.4±43.6 HU 
[range, 62 to 273 HU]; mean enhancement during EP: 
102.2±31.4 HU (range, 36 to 201)]. On the other hand, be-
nign renal masses showed less contrast enhancement; 
mean enhancement was less than 100 HU during all MDCT 
phases [during CMP: 92.8±41.1 HU (range, 54 to 143); dur-
ing NP: 99.3± 42.4 HU (range, 68 to 229); during EP: 
89.4±33.5 HU (range, 44 to 180)]. Overall, the mean attenu-
ation value on the CMP and the NP was significantly higher 
in cases with RCC than in benign lesions (Table 2).
The peak phase enhancement was different for each his-
topathological subtype of the small renal masses. Most of 
the clear cell types of RCC (60%) showed a peak enhance-
ment on the CMP; however, all cases of AML and six of eight 
cases of oncocytoma showed gradual enhancement with a 
peak attenuation value on the NP. For the traditional 
MDCT criteria for lesion characterization, namely, the 
morphologic features and the pattern and degree of con-
trast attenuation of the lesion, the multivariate analysis 
with logistic regression model showed that only the mean 
attenuation value on the CMP had a statistically sig-
nificant correlation; this was found whether the lesions 
were benign or malignant (p=0.021) (Table 3).
Combining the gender and mean attenuation value on 
the CMP showed 94% sensitivity, 41% specificity, 86% pos-
itive predictive value, and 64% negative predictive value.
The ROC curve analysis showed that the cutoff value 
with the highest accuracy for characterization of small re-
nal masses was 87 HU on the CMP and 73 HU on the NP. 
The area under the curve for the CMP was 0.785 (95% con-
fidence interval: 0.667-0.902), and that for the NP was 
0.717 (95% confidence interval: 0.579-0.854) (Fig. 1).
Although all except three benign renal masses (two onco-
cytomas, one AML) showed homogeneous enhancement 
during all phases of the MDCT, 41 out of 67 (61%) RCC le-
sions showed heterogeneous enhancement; the differences 
were statistically significant (p=0.002).
DISCUSSION
Renal parenchymal tumors are a very heterogeneous 
group of lesions, ranging from benign to highly aggressive. 
Accordingly, the morphologic features and the degree and 
pattern of enhancement vary significantly depending on 
the architecture and subtype of the tumor; the findings 
show a considerable amount of overlap. Therefore, the 
characterization of renal parenchymal tumors by use of 
imaging modalities can pose considerable difficulties.
The precise preoperative prediction of the histological 
type of lesion may be helpful not only for determining the 
appropriate treatment plan, such as the extent of the pre-
operative evaluation and surgery, but also in counseling 
the patient preoperatively.
To improve the detection and characterization of renal 
parenchymal tumors, a dedicated quadriphasic MDCT 
protocol was used in this study. The images obtained only 
during the CMP phase failed to identify many of the small 
renal masses that were easily seen on the NP [4,5]. 
Although as in other studies [6,7], RCC was the most 
common lesion, in this series, 67 (80%) out of 84 small renal 
masses less than 4 cm in diameter (a significant fraction 
of small solitary renal masses that were presumed to be 
RCC) had a benign final pathology. The overall rate of be-
nign tumors was 20% in this group of patients. These re-
sults are consistent with previously published reports that 
16 to 27% of small renal masses less than 4 cm are likely 
to be benign [8-10]. Korean J Urol 2012;53:159-164
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In this series, the male-to-female ratio was 2.9:1, which 
was statistically significant. This finding is consistent with 
previously published reports of a male-to-female predom-
inance of 3:2 [11].
Furthermore, in this study, the attenuation value was 
the most useful parameter for differentiating small renal 
masses, especially on the CMP. RCC showed strong en-
hancement, regardless of the subtype, during the three 
phases of imaging after contrast injection. In addition, 
RCC showed a more heterogeneous enhancement, where-
as most of the benign small renal masses showed homoge-
neous enhancement.
The findings of prior studies are consistent with the re-
sults of this study. A study reported by Kim et al. [12] 
showed that RCC had strong enhancement on biphasic CT, 
with a contrast enhancement of over 100 HU on the CMP, 
at 115±48 HU, compared with the level of enhancement on 
the EP, at 62±25. Jinzaki et al. [13] compared the degree 
and pattern of contrast enhancement on the CMP and late 
NP with the findings of 40 renal neoplasms smaller than 
3.5 cm. All clear cell types of RCCs exhibited a peak attenu-
ation value on the CMP of more than 100 HU (165.0±45.8 
HU), which was significantly higher than among the other 
renal tumors.
Renal oncocytoma is a benign tumor that develops in the 
proximal tubular epithelium. Choudhary et al. [14] reported 
that 18 (64%) of 28 patients with renal oncocytoma showed 
significant enhancement of the tumor, isodense to the renal 
cortex, whereas 10 (36%) lesions were hypodense to the sur-
rounding renal cortex in the nephrographic phase with 20 
HU or more. Furthermore, although large oncocytomas 
can exhibit a central stellate scar on the CT, it was found 
in only three (10%) lesions, all of which were larger than 
4 cm in this study. These CT findings were nonspecific and 
might or might not be observed in RCCs and therefore can-
not be used as a determinant of the subtypes of renal 
tumors. Davidson et al. [15] also reported that most renal 
oncocytomas smaller than 3 cm showed homogeneous en-
hancement on all sections of contrast-enhanced CT with-
out a central stellate scar. By contrast, RCCs less than 3 
cm in diameter showed that half of the small RCCs had ho-
mogeneous contrast enhancement with a hypoattenuating 
lesion, suggestive of necrosis. Therefore, CT features, such 
as homogeneous enhancement and a central stellate scar, 
were poor predictors of the diagnosis of oncocytoma. Bird 
et al. [3] investigated enhancement and washout values ob-
tained by MDCT to distinguish oncocytoma from RCC in 
tumors ＜4 cm. This study demonstrated that CMP en-
hancement greater than 500% and washout values of 
greater than 50% are exclusively seen in renal oncocy-
tomas.
In the case of AML, it is composed of various amounts of 
mature adipose tissue, smooth muscle, and thick-walled 
abnormal vessels. The presence of intra-tumor fat on the 
MDCT, measuring less than -30 HU on the unenhanced 
scan, is indicative of an AML [16,17]. Therefore, if sufficient 
fat is present on macroscopic detection, most AMLs, even 
when quite small, can be diagnosed readily by MDCT. 
However, AMLs with minimal fat may have undetectable 
fat on CT or magnetic resonance imaging. This makes them 
difficult to differentiate from RCCs [18,19]. Six cases of 
AML in this study may also have had minimal fat. This ex-
plains why an experienced genitourinary radiologist thou-
ght them to be RCC on preoperative imaging of these lesions.
The limitations of this study include the following. The 
enhancement pattern could vary according to contrast in-
jection variables and scan delay times. Therefore, the 
threshold value we have reported is applicable only to pa-
tients with similar contrast injection protocols and scan de-
lay times. This was a retrospective study. In addition, the 
number of benign small renal masses was relatively small 
for the analysis of the MDCT features that differentiate 
malignancies from benign masses. Because of the small 
number of renal masses, this study did not evaluate differ-
ences of each subtype of RCC. This is due to the low fre-
quency of radiologically indeterminate or suspected malig-
nant lesions. In most cases, the mass is confirmed as benign 
by pathology due to the accuracy of the helical MDCT with 
optimized kidney scan protocol and thin collimation with 
multiphasic volumetric data acquisition. Therefore, fur-
ther investigations with a much larger number of cases will 
be necessary in the future.
CONCLUSIONS
For the characterization of small renal mass, the degree of 
enhancement on the CMP is the most valuable parameter. 
Furthermore, the heterogeneous enhancement pattern 
and degree of enhancement on the NP can provide in-
formation for differentiating small renal masses from 
malignancies. This could aid in decisions about treatment 
by differentiating malignant tumors, which require surgi-
cal intervention, from benign lesions, which may be ad-
equately managed by conservative treatment.
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